Telix to Explore PSMA-PET Imaging in Collaborations with EDAP and Profound

Telix Pharmaceuticals Limited will pursue collaborations with EDAP TMS S.A. and Profound Medical Corp., companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer. Telix’ goal is to advance the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.

The collaborations will explore the investigational use of Telix’s PSMA-PET imaging agents Gozellix (kit for the preparation of gallium Ga 68 gozetotide) and Illuccix (kit for the preparation of gallium Ga 68 gozetotide) with robotic high-intensity focused ultrasound (HIFU), and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation (TULSA).

Telix’s intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement.

“Precision medicine requires precision treatment strategies,” said Kevin Richardson, CEO, Telix Precision Medicine. “As disruptive technologies continue to transform prostate cancer care, we believe PSMA-PET imaging has the potential to play an important role in helping inform clinical decision-making across a range of minimally invasive and image-guided treatment approaches. We are excited to explore collaborations with market leaders in EDAP and Profound that may further advance personalized care for patients.”